Duopharma Biotech Bhd (XKLS:7148) ROCE %: 16.23% (As of Mar. 2026)


XKLS:7148 Duopharma Biotech Bhd XKLS:7148
83 GF Score
Price RM1.20
GF Value RM1.52
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd ROCE %?

Duopharma Biotech Bhd XKLS:7148 83 ROCE % is 16.23% as of Mar. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 83/100 and a GF Value™ of RM1.52 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Duopharma Biotech Bhd's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.23%.

Duopharma Biotech Bhd  (XKLS:7148) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Duopharma Biotech Bhd ROCE % Related Terms

Duopharma Biotech Bhd ROCE % Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd ROCE % Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.71 9.94 7.58 8.90 11.91

Duopharma Biotech Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.31 10.84 12.25 10.83 16.23
XKLS:7148
83GF Score
Duopharma Biotech Bhd XKLS:7148
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd ROCE % Calculation

Duopharma Biotech Bhd's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=139.072/( ( (1377.833 - 177.985) + (1451.16 - 314.955) )/ 2 )
=139.072/( (1199.848+1136.205)/ 2 )
=139.072/1168.0265
=11.91 %

Duopharma Biotech Bhd's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=184.028/( ( (1451.16 - 314.955) + (1446.457 - 314.502) )/ 2 )
=184.028/( ( 1136.205 + 1131.955 )/ 2 )
=184.028/1134.08
=16.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.23% mean?
Duopharma Biotech Bhd (XKLS:7148) has a ROCE % of 16.23% as of Mar. 2026.
Is Duopharma Biotech Bhd's ROCE % too high?
Duopharma Biotech Bhd's current ROCE % is 16.23%. The Drug Manufacturers industry median ROCE % is 7.00. Duopharma Biotech Bhd's value of 16.23% is 132% above this industry median. Overall, Duopharma Biotech Bhd has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's ROCE % compare to ZTS and UTHR?
Duopharma Biotech Bhd's ROCE % of 16.23% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Duopharma Biotech Bhd's value of 16.23% is 132% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current ROCE % of 16.23% is 132% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current ROCE % is 16.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.52, compared to a current price of RM1.20 — trading 21.1% below its estimated fair value. The current ROCE % is 16.23% and 132% above the Drug Manufacturers industry median of 7.00. Duopharma Biotech Bhd's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current ROCE % is 16.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.20 is trading 21.1% below its estimated GF Value™ of RM1.52. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • ROCE %: 16.23%
  • GF Value™: RM1.52 vs. price of RM1.20 (21.1% below fair value)
  • GF Score™: 83/100 with 4 warning signs
  • Industry Position: 132% above the Drug Manufacturers median

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
83GF Score

Get the complete analysis for XKLS:7148

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.20
Price
RM1.52
GF Value